[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603230":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":25,"overallOfficials":11,"centralContacts":29,"locations":39,"responsibleParty":57,"collaborators":11,"id":59,"slug":11,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Beijing Suncadia Pharmaceuticals Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The incidence and severity of adverse events",null,"during the study period About 48 months，",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":11,"interventionNames":23},"SHR-1918","EXPERIMENTAL",[24],"Drug: SHR-1918",[26],{"type":27,"name":21,"description":21,"armGroupLabels":28,"otherNames":11},"DRUG",[21],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Meng Sun","CONTACT","+86 18036618718","meng.sun@hengrui.com",{"name":36,"role":32,"phone":37,"phoneExt":11,"email":38},"Chao Lyu","+86 13810733217","chao.lv.cl1@hengrui.com",[40],{"facility":41,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Xiangya Second Hospital of Central South University","Changsha","Hunan","410007","China","CN",{"type":48,"coordinates":49},"Point",[50,51],112.97087,28.19874,{"lat":51,"lon":50},[54],{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Daoquan Peng","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603230",false,"NCT07133815","Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia","A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Subjects who received and completed the SHR-1918-301 study treatment in previous studies and were deemed to have therapeutic benefits by the researchers\n\nExclusion Criteria:\n\n1. Known to be allergic to the investigational drug or any component of the investigational drug, or to have experienced severe allergic reactions to other antibody drugs;\n2. History of malignant tumors in the past 5 years;\n3. There are serious concurrent diseases\n4. Pregnant or lactating women;\n5. The researchers determined that the subjects had poor compliance or any inappropriate factors for participating in this trial","ALL","12 Years",{"count":68,"type":69},55,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients",[75],"Homozygous Familial Hypercholesterolemia","NOT_YET_RECRUITING","2025-08-14",{"date":79,"type":80},"2025-08-21","ACTUAL",{"date":82,"type":69},"2025-08",{"date":84,"type":69},"2027-12",{"name":5,"class":6},1]